Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.00 +1.5% SILVER 56.86 +1.8% COPPER 6.57 −1.4% OIL 95.28 +0.2% PALLADIUM 1126.25 +2.7% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 −5.8% TECT 1.66 −6.2% TOM 0.135 −15.6% FVL 0.900 −7.2% HART 0.195 +2.6% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +1.2% SAO 0.050 +0.0% SEND 0.750 −20.2% MD 0.330 −2.9% ASM 6.97 −5.6% TK 0.400 −1.2% GOLD 4170.00 +1.5% SILVER 56.86 +1.8% COPPER 6.57 −1.4% OIL 95.28 +0.2% PALLADIUM 1126.25 +2.7% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 −5.8% TECT 1.66 −6.2% TOM 0.135 −15.6% FVL 0.900 −7.2% HART 0.195 +2.6% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +1.2% SAO 0.050 +0.0% SEND 0.750 −20.2% MD 0.330 −2.9% ASM 6.97 −5.6% TK 0.400 −1.2%

Healthcare

Page 20
  1. May 12, 2026 · 17:05 · CSCI · Routine −

    COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

    COSCIENS Biopharma Inc. Reports Q1 2026 Results

    01
  2. May 12, 2026 · 17:02 · PREV · Routine −

    PreveCeutical Closes Dilutive Financing Amidst Cash Burn Concerns

    PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

    02
  3. May 12, 2026 · 17:00 · EPRX · Routine +

    Eupraxia Pharmaceuticals Secures H2 2028 Runway with Strong Clinical Data, But Phase 2b Catalyst Remains Key

    Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

    03
  4. May 12, 2026 · 16:50 · IOT · Material −

    Innovotech’s revenue collapse exposes client concentration flaw as transformation costs mount

    Innovotech Inc. Reports Q1 2026 Financial Results and Operational Update

    04
  5. May 12, 2026 · 16:06 · DTR · Material +

    DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

    DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics

    05
  6. May 12, 2026 · 10:06 · EXE · Routine +

    Extendicare Confirms CBI Integration Success with Pro Forma Financials; Debt Restructuring Solidifies Investment Grade Status

    Extendicare Files Business Acquisition Report in connection with the CBI Home Health Acquisition

    06
  7. May 12, 2026 · 09:00 · BPC · Material +

    Precision Peptide Inks Exclusive MMA Fight-Sports Marketing Pact to Tap $300B Wellness Market

    Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

    07
  8. May 12, 2026 · 09:00 · OTC · Routine +

    Ocumetics Manufacturing Milestone Validates Design Pivot Amidst Capital Pressures

    Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens

    08
  9. May 12, 2026 · 08:30 · SURE · Routine +

    SureNano Advances GLP-1 Pipeline Amidst Dilution Concerns and Clinical Milestones

    SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform

    09
  10. May 12, 2026 · 08:30 · BPC · Material +

    Precision Peptide Taps MMA’s 5 Million Combat Sports Fans to Muscle Into $300 Billion Wellness Market

    MMA.INC (NYSE American: MMA) Enters Exclusive 50/50 Revenue Share Peptide Partnership with Precision Peptide (CSE: BPC)

    10
  11. May 12, 2026 · 08:00 · AIDR · Routine +

    Strategic Education Partnership Masks Liquidity Concerns Amidst Rapid Revenue Growth

    Rocket Doctor and University of Toronto Launch Digital Health Observership Program for Physician Assistant Students

    11
  12. May 12, 2026 · 07:31 · BPC · Material +

    BPC plugs into MMA’s 5 million followers in a revenue-share gamble that could body-slam needle-phobia and vault peptides into the mainstream.

    The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited

    12
  13. May 12, 2026 · 07:30 · BCT · Routine +

    BriaCell Therapeutics Advances Phase 3 Enrollment Amidst Stock Consolidation Near Historic Lows

    BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

    13
  14. May 12, 2026 · 07:00 · MDNA · Routine +

    Next-Generation IL-2 Superkine Developer

    Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

    14
← Newer Older →